Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)

Ding, C and Jones, G (2006) Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline). Current Opinion in Investigational Drugs, 7 (5). pp. 464-472. ISSN 1472-4472

PDF - Full text restricted - Requires a PDF viewer
251Kb

Official URL: http://www.biomedcentral.com/1472-4472/7?issue=5

Abstract

Belimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.

Item Type:	Article
Additional Information:	restricted - published by Thompson
ID Code:	3609
Deposited By:	Dr Changhai / C Ding
Deposited On:	07 Apr 2008 11:36
Last Modified:	18 Jul 2008 20:43
ePrint Statistics:	View statistics for this ePrint

Repository Staff Only: item control page